These findings are further supported by the work of Nazari et al,20which also showed no association of serum VEGF levels and the prediction of VTE in patients with glioma (hazard ratio per double increase: 0.995, 95% CI 0.640–1.548,p = 0.983). The gene discussed is VEGFA; the disease is central nervous system cancer.